NATR trades 185.2% below Wall Street's consensus target of $31.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes NATR achieves its forward estimates and maintains a stable P/E multiple of 10.3x. This scenario reflects the blended consensus of 4 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, Nature's Sunshine Products, Inc. (NATR) has a Wall Street consensus price target of $31.00, based on estimates from 4 covering analysts. With the stock currently trading at $10.87, this represents a potential upside of +185.2%. The company has a market capitalization of $191M.
Analyst price targets range from a low of $25.00 to a high of $37.00, representing a 39% spread in expectations. The median target of $31.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 2 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, NATR trades at a trailing P/E of 13.3x and forward P/E of 10.3x. Analysts expect EPS to grow +6.9% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $11.20, with bear and bull scenarios of $7.05 and $14.75 respectively. Model confidence stands at 48/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 USNAUSANA Health Sciences, Inc. | $252M | $13.63 | $35.00 | +156.8% | Hold | 7.8x | 8 |
 NUSNu Skin Enterprises, Inc. | $199M | $4.10 | $11.00 | +168.3% | Hold | 5.0x | 11 |
 NHTCNatural Health Trends Corp. | $8M | $0.77 | — | — | — | — | — |
 MTEXMannatech, Incorporated | $16M | $8.11 | — | — | — | — | — |
 HLFHerbalife Nutrition Ltd. | $1.6B | $15.28 | $21.00 | +37.4% | Buy | 6.3x | 26 |
 PLBYPlayboy, Inc. | $150M | $1.29 | $12.63 | +879.1% | Buy | — | 8 |
 AGENAgenus Inc. | $298M | $7.15 | $25.00 | +249.7% | Buy | 26.7x | 12 |
 NBIXNeurocrine Biosciences, Inc. | $16.6B | $164.63 | $203.41 | +23.6% | Buy | 22.5x | 37 |
 AMZNAmazon.com, Inc. | $2.8T | $259.30 | $328.48 | +26.7% | Buy | 20.2x | 96 |
 WMTWalmart Inc. | $1.0T | $125.52 | $129.22 | +3.0% | Buy | 43.4x | 66 |
Quick answers to the most common questions about buying NATR stock.
The consensus Wall Street price target for NATR is $31, representing 185.2% upside from the current price of $10.87. With 4 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
NATR has a consensus rating of "Buy" based on 4 Wall Street analysts. The rating breakdown is mixed, with 2 Hold ratings making up the largest segment. The consensus 12-month price target of $31 implies 185.2% upside from current levels.
With a forward P/E of 10.3033x, NATR trades at a relatively low valuation. The consensus target of $31 implies 185.2% appreciation, suggesting meaningful undervaluation.
The most bullish Wall Street analyst has a price target of $37 for NATR, while the most conservative target is $25. The consensus of $31 represents the median expectation. Our quantitative valuation model projects a bull case target of $15 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
NATR is lightly followed, with 4 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 2 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month NATR stock forecast based on 4 Wall Street analysts shows a consensus price target of $31, with estimates ranging from $25 (bear case) to $37 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $11, with bear/bull scenarios of $7/$15.
Our quantitative valuation model calculates NATR's fair value at $11 (base case), with a bear case of $7 and bull case of $15. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 48/100.
NATR trades at a forward P/E ratio of 10.3x based on next-twelve-months earnings estimates compared to a trailing P/E of 13.3x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on NATR, with a "Buy" consensus rating and $31 price target (185.2% upside). 2 of 4 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
NATR analyst price targets range from $25 to $37, a 39% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $31 consensus represents the middle ground. Our model's $7-$15 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.